Inhibition of DPP-4 is a novel therapeutic option to raise the concentration of active GLP-1 and extend its activity to improve hyperglycemia by stimulating glucose-induced pancreatic insulin secretion while inhibiting glucagon production (Mulvihill and Drucker., 2014). The gene discussed is GCG; the disease is Hyperglycemia.